---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-079107"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2023-07-07T23:59:59+00:00"
generated_at: "2026-06-13T10:54:50.175464+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cyclacel gets 180-day Nasdaq extension to Jan 2, 2024 to regain $1.00 bid price compliance

## Summary
- Received extension on July 5, 2023; must comply by January 2, 2024.
- Previously disclosed non-compliance on Jan 6, 2023; original cure period ended July 3, 2023.
- Company intends to cure via reverse stock split if necessary, within ten business days before extension expires.
- If not cured by Jan 2, 2024, Nasdaq will issue delisting notice; Company may appeal to Hearing Panel.

## SEC filing metadata
- accession: 0001104659-23-079107
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2023-07-07T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465923079107/0001104659-23-079107-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465923079107/tm2320788d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-079107
- JSON: https://secwatch.observer/filing/0001104659-23-079107.json
- Plain text: https://secwatch.observer/filing/0001104659-23-079107.txt

## Key facts
- Listing & Compliance Notices
  Bio Green Med Solution, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: July 5, 2023, Cyclacel Pharmaceuticals, Inc. (the “ Company ”) received a letter (the “ Extension Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) notifying the Company that Nasdaq has granted the Company a 180-day extension, or until January 2, 2024 (the “ Extension Period ”), to regain compliance with the requirement for the Company’s common stock, par value $0.001 per share (“ Common Stock ”), to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465923079107/0001104659-23-079107-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.